Genmab A/S (GMAB) has a current Price-to-Book (P/B) ratio of 3.37. Compared to its 3-year average P/B ratio of 3.53, the current P/B ratio is approximately -4.56% higher. Relative to its 5-year average P/B ratio of 5.17, the current P/B ratio is about -34.77% higher. Genmab A/S (GMAB) has a Forward Free Cash Flow (FCF) yield of approximately 6.85%. Compared to its 3-year average FCF yield of 5.69%, the current FCF yield is approximately 20.30% lower. Relative to its 5-year average FCF yield of 4.10%, the current FCF yield is about 67.12% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for GMAB competitors is 7.23, providing a benchmark for relative valuation. Genmab A/S Corp (GMAB.O) exhibits a P/S ratio of 4.63, which is -35.99% above the industry average. Given its robust revenue growth of 14.63%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of GMAB increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of GMAB in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is GMAB currently overvalued or undervalued?

What is Genmab A/S (GMAB) fair value?

GMAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Genmab A/S (GMAB) is between 21.80 to 93.97 according to relative valuation method.

How does GMAB's valuation metrics compare to the industry average?

The average P/S ratio for GMAB's competitors is 7.23, providing a benchmark for relative valuation. Genmab A/S Corp (GMAB) exhibits a P/S ratio of 4.63, which is -35.99% above the industry average. Given its robust revenue growth of 14.63%, this premium appears unsustainable.

What is the current P/B ratio for Genmab A/S (GMAB) as of Mar 03 2026?

As of Mar 03 2026, Genmab A/S (GMAB) has a P/B ratio of 3.37. This indicates that the market values GMAB at 3.37 times its book value.

What is the current FCF Yield for Genmab A/S (GMAB) as of Mar 03 2026?

As of Mar 03 2026, Genmab A/S (GMAB) has a FCF Yield of 6.85%. This means that for every dollar of Genmab A/S's market capitalization, the company generates 6.85 cents in free cash flow.

What is the current Forward P/E ratio for Genmab A/S (GMAB) as of Mar 03 2026?

As of Mar 03 2026, Genmab A/S (GMAB) has a Forward P/E ratio of 17.91. This means the market is willing to pay $17.91 for every dollar of Genmab A/S's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Genmab A/S (GMAB) as of Mar 03 2026?

As of Mar 03 2026, Genmab A/S (GMAB) has a Forward P/S ratio of 4.63. This means the market is valuing GMAB at $4.63 for every dollar of expected revenue over the next 12 months.

GMAB Valuation